Premium
Clearance of Imidapril, an Angiotensin‐Converting Enzyme Inhibitor, During Hemodialysis in Hypertensive Renal Failure Patients: Comparison With Quinapril and Enalapril
Author(s) -
Tsuruoka Shuichi,
Kitoh Yasuhiko,
Kawaguchi Atsuhiro,
Sugimoto Kohichi,
Hayasaka Tokie,
Saito Tetsuo,
Fujimura Akio
Publication year - 2007
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270006293751
Subject(s) - enalaprilat , quinapril , enalapril , medicine , hemodialysis , ace inhibitor , angiotensin converting enzyme , blood pressure , endocrinology , urology , pharmacology
The dialyzability of imidaprilat, an active metabolite of the angiotensin‐converting enzyme (ACE) inhibitor imidapril, was determined and compared with those of enalaprilat and quinaprilat in hypertensive patients on chronic hemodialysis. Imidapril (5 mg/d, n = 6), enalapril (2.5 mg/d, n = 6), or quinapril (2.5 mg/d, n = 6) was given for at least 8 weeks prior to the trial. During dialysis, enalaprilat, but not imidaprilat or quinaprilat, concentrations in both sides decreased significantly. Compared to enalaprilat, the dialyzabilities of imidaprilat and quinaprilat were significantly lower (dialyzer clearance [mL/min/m 2 ]: enalaprilat, 41.8 ± 7.4; imidaprilat, 19.0 ± 7.8; quinaprilat, 8.9 ± 1.3). The dialyzabilities of the 3 drugs were negatively correlated with their respective protein‐binding rates. During hemodialysis, blood pressure did not change significantly in any group. These results suggest that imidapril provides good blood pressure control without a large fluctuation of drug concentration in hypertensive patients undergoing chronic hemodialysis.